Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs PepsiCo, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while PepsiCo, Inc. trades at $137.9 (market cap $187.51B). The key difference: PepsiCo, Inc. is far larger — about 4.7× Alnylam Pharmaceuticals, Inc.'s market cap, and PepsiCo, Inc. pays a 4.31% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PEP | |
|---|---|---|
Market Cap | $39.89B | $187.51B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $170.44 |
52-Week Low | $278.09 | $133.81 |
Enterprise Value | $38.15B | $230.01B |
Dividend Yield | — | 4.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
PepsiCo (PEP) trades at $137.38, down 0.35% on the day, with technical indicators showing bearish momentum. The stock has consistently beaten earnings expectations in recent quarters, with Q3 2026 results pending. Strong profitability metrics include a 10.78% net income margin and 51.59% ROE, though revenue growth remains modest. Recent news highlights price adjustments for snack products and sponsorship changes.
The outlook is mixed: analyst consensus targets $159.27 (16% upside) with 33% buy ratings, but technicals are bearish. Key risks include consumer pushback on pricing and competitive pressures. The upcoming Q1 2026 earnings report will be critical for confirming the North American turnaround story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
